BTRC

Across TCGA pan-cancer cohorts, BTRC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BTRC data layer compared with 18 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BTRC mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BTRC expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LUAD are the cancer types where BTRC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.863	0.395	.038	12	view →
GBM	DFS	Median	All	0.923	0.614	.016	11	view →
LUAD	DFS	Median	II,III,IV	0.671	1.000	.013	9	view →
LSCC	OS	Tertile	III,IV	0.909	0.379	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BTRC–HNSC (OS)

Open the HNSC breakdown →